institutional access

You are connecting from
Lake Geneva Public Library,
please login or register to take advantage of your institution's Ground News Plan.

Published 1 day ago • loading... • Updated 1 day ago

CAGE Bio Reports Strong Results from its Phase 2b Atopic Dermatitis Trial

Summary by The Billings Gazette

The investigational topical drug CGB-500 outperformed efficacy benchmarks while meeting safety endpoints59% of patients achieved IGA treatment success71% of patients experienced ≥4-point improvement in worst itch

17 Articles

17 Articles

Helena Independent Record

+16 Reposted by 16 other sources

CAGE Bio Reports Strong Results from its Phase 2b Atopic Dermatitis Trial

The investigational topical drug CGB-500 outperformed efficacy benchmarks while meeting safety endpoints59% of patients achieved IGA treatment success71% of patients experienced ≥4-point improvement in worst itch

1 day ago·Helena, United States

Read Full Article

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year

Coverage Details

Total News Sources17

Leaning Left1Leaning Right0Center9Last Updated3 hours agoBias Distribution

90% Center

Bias Distribution

90% of the sources are Center

90% Center

+4

Untracked bias

Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

The Billings Gazette broke the news in Billings, United States 1 day ago on Thursday, September 4, 2025.

Sources are mostly out of (0)

Similar News Topics

Similar News Topics